Searchable abstracts of presentations at key conferences in endocrinology

ea0026p263 | Pituitary | ECE2011

Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant

Chieffo C , Ryan M , Bai S , Hu X , Decker S , Quandt H , Frohman L , Gadelha M

Two randomized open-label, phase II studies evaluated an octreotide hydrogel implant to suppress serum GH and IGF1 levels in adult acromegaly patients. Implants were inserted subcutaneously in the upper arm for 6 months. Patients in study 1 received 1 (n=5) or 2 (n=6) 52-mg octreotide (60 mg octreotide acetate) hydrated implants; patients in study 2 received a hydrated (H) or nonhydrated (NH) 84-mg octreotide acetate implant (n=34, 1 excluded from efficacy...

ea0007p107 | Endocrine tumours and neoplasia | BES2004

Prevalence of hypopituitarism in patients with prolactin-secreting pituitary microadenomas

Behan L , Seoighe D , Agha A , Sherlock M , Ryan J , Rogers B , Thompson C

Microprolactinomas are considered not to cause pituitary hormone dysfunction, but there is little data available on the prevalence of hormone deficiencies. We aimed to establish the frequency of pituitary hormone dysfunction in patients with hyperprolactinaemia.We examined the casenotes of 124 consecutive patients (85 females) with documented hyperprolactinemia from our pituitary data-base. 52 patients had macroadenomas (tumour > 1cm diameter), 64 mic...